Business Context and Reporting Period
This Form 8-K is filed by Nephros, Inc. for the reporting period of January 22, 2009. The filing addresses a critical corporate event regarding the status of the company's common stock listing on the NYSE Alternext US LLC (formerly the American Stock Exchange or "AMEX").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory and listing status updates rather than financial performance data.
Material Changes
- Trading Suspension: On January 22, 2009, AMEX suspended trading in Nephros, Inc.'s common stock effective immediately.
- Delisting Cause: The suspension follows a January 8, 2009 notice of intent to delist due to noncompliance with three listing standards.
- Trading Venue Shift: While the formal delisting is not yet effective, the stock is no longer traded on AMEX. Quotations are now available in the Pink Sheets under the symbol "NEPH."
Outlook, Risks, and Management Commentary
- OTC Bulletin Board Application: Management has identified a market maker to apply for quotation on the OTC Bulletin Board.
- Timeline Uncertainty: The process to list on the OTC Bulletin Board could take several weeks if successful.
- Risk of Delisting: The company faces the risk of remaining unlisted on a major exchange, potentially impacting liquidity and investor access.
Key Facts for Investor Verification
- Verify the current trading status and symbol ("NEPH") on the Pink Sheets.
- Confirm the timeline and success of the OTC Bulletin Board application.
- Review the specific listing standards with which the company is noncompliant to assess the path to potential relisting.
- Check for subsequent filings regarding the formal delisting effective date.